Adenocarcinoma in situ of the uterine cervix is a premalignant glandular condition. Adenocarcinoma in situ is the only known precursor to cervical adenocarcinoma, and appropriate management can prevent the occurrence of invasive disease in many cases . The usual interval between clinically detectable adenocarcinoma in situ and early invasion appears to be at least five years, suggesting ample opportunity for screening and intervention [2,3].
Glandular neoplasia of the uterine cervix is less common than squamous neoplasia, comprising one quarter of all annual cervical cancers diagnoses in the United States . Over the past few decades, however, the incidence of adenocarcinoma in situ and invasive adenocarcinoma has increased .
The diagnosis and management of cervical adenocarcinoma in situ are reviewed here. Related topics are discussed separately, including:
EPIDEMIOLOGY AND RISK FACTORS
The average age of women at diagnosis of cervical adenocarcinoma in situ (AIS) is 36.9 years, based upon a meta-analysis that included 33 studies with 1278 patients with a diagnosis of AIS on cervical cone biopsy .